<DOC>
	<DOC>NCT00122304</DOC>
	<brief_summary>The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH</brief_summary>
	<brief_title>Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>PNH &gt; 6 months Type III PNH red blood cell (RBC) clone by flow cytometry &gt;10% At least one transfusion in the past 2 years but no more than 3 transfusions in the past 12 months; or personal beliefs that preclude the use of transfusion with severe hemolytic PNH Lactate dehydrogenase (LDH) &gt;1.5 x upper limit of normal Must avoid conception Willing and able to give written informed consent Platelet count of &lt;30,000/mm3 Absolute neutrophil count &lt;500/ul Active bacterial infection Hereditary complement deficiency History of bone marrow transplantation Participation in any other investigational drug trial or exposure to other investigational agent, device or procedure within 30 days Pregnant, breastfeeding, or intending to conceive History of meningococcal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>